Drugs / 3HP-2827
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06287918 | Jun 2026 → Mar 2028 expected | — | 3H (Suzhou) Pharmaceuticals Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06378593 | Jun 2024 → Jun 2028 expected | neoplasm | 3H (Suzhou) Pharmaceuticals Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 3HP-2827 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06378593 ↗ |
| Route | Oral | “3HP-2827 will be administered orally once daily in 28-day cycles.” NCT06287918 ↗ |